Royalty Report: Drugs, Disease, Diabetes Treatment – Collection: 253975

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Disease
  • Diabetes Treatment
  • obesity
  • Therapeutic
  • Drug Discovery
  • Molecular

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 253975

License Grant
Licensor of the United Kingdom grants an exclusive, even as to Licensor,  license under the Licensor Rights to research, develop, make, have made, use, sell, have sold, offer for sale and import/export Product(s) in the Field in the Territory, together with the right to grant sublicenses.
License Property
Product means any product which includes as an active pharmaceutical ingredient known as Licensors 010 or a GKA Back-up for use either alone or in combination with one or more other therapeutically active substances.  PSN010 is (2R)-2(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl) proplonamide or a salt or other derivative.

The patents include Tricyclo substituted amide compounds;  Tricyclo substituted amide glucokinase activator compounds;  Substituted phenylacetamidcs and their use as glucokinasc activators;   Enantioselective process;  Fluorination process of protected aminothiazole; and, Tricyclo Substituted Amides.

Glucokinase activators have a dual effect in the pancreas and the liver resulting in increased hepatic glucose uptake in the liver and stimulated insulin secretion by the pancreas.

Glucokinase Activator (GKA) includes the lead compound PSN010.  GKAs like PSN010 are designed to attenuate hyperglycemia by rapidly lowering blood glucose levels through a dual mechanism of increasing glucose uptake in the liver and potentiating insulin secretion from the pancreas. PSN010 is currently in Phase I clinical trials.

PSN010 was discovered and developed in-house through Licensor’s diabetes and obesity research efforts.

Field of Use
GKAs represent a new approach to diabetes therapy.

IPSCIO Record ID: 215177

License Grant
Pursuant to this agreement, the Parties agree to collaborate on an exclusive basis in the Development and Commercialization of Product in the Field.

Licensor grants an exclusive license in the Territory, with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Licensor grants a non-exclusive, worldwide license, including the right to sublicense in conjunction with a sublicense permitted by this agreement, to use the Licensors Marks on Product packaging, labeling, advertising and Promotional Material.

For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Each Party grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.

License Property
The Neogenesis patents are claiming differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4.

The Compound means exendin-4, an amino acid sequence.

AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.

The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).

U.S. 5,424,286

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.

This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.

IPSCIO Record ID: 203477

License Grant
Pursuant to this agreement, the Parties agree to collaborate on an exclusive basis in the Development and Commercialization of Product in the Field.

Licensor grants an exclusive license in the Territory except for the U.S. with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory except for the U.S. as contemplated by this Agreement, and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Licensor grants a non-exclusive, worldwide license, including the right to sublicense, to use the Licensor Marks on Product packaging, labeling, advertising and Promotional Material.

For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement, and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Each Party hereby grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.

License Property
The Neogenesis patents are claiming differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4.

The Compound means exendin-4, an amino acid sequence.

AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.

The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).

U.S. 5,424,286

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.

This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.

IPSCIO Record ID: 203348

License Grant
The Parties enter into an agreement for Licensor to design and synthesize glucokinase activators (GKAs) based on the lead molecules provided by Licensee and input obtained from the in vitro and in vivo testing of the molecules to be synthesized by Licensor as GKAs.

Licensee shall provide lead molecules that will be used by Licensor to design and synthesize molecules optimized for activation of the Target.

The Parties shall use commercially reasonable efforts to design and synthesize molecules that are optimized for activation of the Target Molecules based on the lead molecules provided by Licensee.

Licensor shall provide the structure of each such Molecule and any information about the Molecule that is available.

Licensor shall promptly assign to Licensee all such related intellectual property.

License Property
The Product means a pharmaceutical product that contains a Molecule,  that is conceived as a part of the Project,  considered by the Joint Committee for synthesis as a Molecule, and which either could have been reduced to practice by Licensor but for the Project ending or is reduced to practice by Licensee, the  Compound.
Field of Use
Licensor shall have the right to use the Molecules for screening purposes, except against the Target.  The target that is to be activated is glucokinase.

Glucokinase is an enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. Glucokinase occurs in cells in the liver and pancreas of humans and most other vertebrates.

IPSCIO Record ID: 239035

License Grant
The option shall provide the Japanese Licensee an exclusive option to obtain an exclusive license to a new Back-up Compound for CS-917 and an exclusive first right to negotiate a new agreement with Licensor
for discovery and commercialization of next generation compounds in the Field.

For the grant of option, Licensor grants to the Japanese Licensee an exclusive option to obtain an exclusive license to any one New Back-up Compound discovered by Licensor during the Discovery Period, and,  of the Restated Agreement and otherwise on the terms and conditions set forth in the Restated Agreement.

For grant of negotiation right with Licensor during the Option Term for a new collaborative research, development and commercialization agreement between the parties for the discovery, development and commercialization of Next Generation Compounds in the Field.

License Property
Back-up Compound means any and all Compounds that have properties, results and effects that are substantially similar to CS-917.

CS-917 means that certain Compound known as CS-917 (also known as MB6322), which is a Licensed Compound under the Restated Agreement.

CS-917, a compound for the treatment of type 2 diabetes, is a prodrug of an orally active, potent and selective inhibitor of fructose-1, 6-bisphosphatase (FBPase), a regulatory enzyme in the pathway responsible for the production of glucose in the liver, known as the gluconeogenesis pathway.

Field of Use
Field means the treatment of Diabetes by means of lowering blood glucose levels by direct suppression of hepatic gluconeogenesis by inhibiting fructose-1, 6-bisphosphatase.

IPSCIO Record ID: 211839

License Grant
The Australian Licensee desires to collaborate with an Australian University for a Project using the Research Expertise and a license of all Intellectual Property in the result of the Project.
License Property
The University has expertise in one or more areas of the Research Fields, and owns or has an exclusive license of the Pre-existing Intellectual Property.  The Patent has been licensed exclusively to the University and is for the Treatment of Obesity.  Products means the products and results of the Project.

Australian Provisional Patent Application No. PO 1085/96 (annexed hereto) entitled “Treatment of Obesity” filed on 18 July 1996.

Field of Use
The primary aim of this research program is to discover novel genes that will be integral to the development of new therapeutic approaches directed at the treatment and prevention of obesity.

The Project means scientific research using the Research Expertise into the role of potential pharmaceutical agents on food intake, body weight control and parameters of insulin resistance and diabetes as examined in studies into therapeutic regulators of food intake and appetite.

IPSCIO Record ID: 378328

License Grant
Licensee was granted an exclusive license to use the MP Patents and know-how to develop products for the development, commercialization and exclusive license of MLR-1023 On October 20, 2021, Licensee expanded the an exclusive licensing agreement with Licensor to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation.
License Property
MLR-1023 (tolimidone) is being developed as a novel therapeutic for Type 1 diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.
Field of Use
The  license of MLR-1023 (tolimidone) is for the purpose of developing a novel therapeutic for Type 1 diabetes.

Field of use is for the treatment of diabetes as well as for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.

Diabetes is a chronic (long-lasting) health condition that affects how your body turns food into energy. Most of the food you eat is broken down into sugar (also called glucose) and released into your bloodstream. When your blood sugar goes up, it signals your pancreas to release insulin.

Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.

Pulmonary inflammation is acute lung inflammation.  In the lung, inflammation is usually caused by pathogens or by exposure to toxins, pollutants, irritants, and allergens. During inflammation, numerous types of inflammatory cells are activated.

IPSCIO Record ID: 372528

License Grant
Licensor hereby grants to Licensee and its Affiliates, and Licensee hereby accepts on its and their behalf, a sole and exclusive license, with full rights to sublicense , under the Licensor Know-How, to (a) develop, use, sell, offer for sale, and import Licensed Products containing the Compound, Derivative or Additional Licensed Compound in the Field, in the Territory, and (b) make and have made Licensed Products in the Territory for such development, use, sale, offering for sale, and importation. Licensor hereby assigns to Licensee all of its rights, title and interest in and to the Licensor Patent Rights.
License Property
US Patent #7,317,125 – Diacylglycerol acyltransferase inhibitors

Licensed Product means any product containing a Compound, a Derivative or an Additional Licensed Compound, including all formulations, dosages, and dosage forms thereof.

Compound means the compound 4-(4-(4-[(2-phenyl-5-trifluoromethyloxazole-4-carbonyl)-amino]-phenyl)-piperidine-1-carbonyl)-cyclohexanecarboxylic acid, also known as RO5131723.

Field of Use
Field means all therapeutic, prophylactic, and other pharmaceutical uses and applications for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Metabolic syndrome is a cluster of conditions that occur together, increasing your risk of heart disease, stroke and type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.